First Trust Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

First Trust Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,900	Closed	-$423K	–	2604
2021 Q4	$423K	Buy	+23,900	New	+$459K	﹤0.01%	2329
2021 Q3	–	Sell	-19,551	Closed	-$386K	–	2667
2021 Q2	$386K	Sell	19,551 -81,995	-81%	-$1.92M	﹤0.01%	2329
2021 Q1	$2.95M	Buy	+101,546	New	+$2.84M	﹤0.01%	1555
2020 Q4	–	Sell	-69,009	Closed	-$1.1M	–	2437
2020 Q3	$1.1M	Buy	+69,009	New	+$1.26M	﹤0.01%	1713

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

First Trust Advisors's NGM Position: Q1 2022 in Review

First Trust Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022, closing a stake of 23,900 shares — an estimated $423K sold.

First Trust Advisors first reported a position in NGM in Q3 2020 and held it in 4 quarters. The position peaked at $2.95M in Q1 2021. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

First Trust Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
First Trust Advisors sold 23,900 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $423K.
First Trust Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
First Trust Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.95M in Q1 2021.
114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on First Trust Advisors's 13F filing for Q1 2022, filed 13 May 2022.